Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

68.20USD
14 Dec 2018
Change (% chg)

$-1.54 (-2.21%)
Prev Close
$69.74
Open
$68.91
Day's High
$69.32
Day's Low
$68.13
Volume
1,593,891
Avg. Vol
1,875,188
52-wk High
$110.20
52-wk Low
$66.62

Select another date:

Thu, Oct 25 2018

Celgene's third-quarter results beat as Otezla sales soar

Celgene Corp on Thursday reported a better-than-expected third-quarter profit as sales of psoriasis drug Otezla and its flagship cancer medicine Revlimid surged, and the biotech company raised its full-year revenue forecast.

UPDATE 2-Celgene's third-quarter results beat as Otezla sales soar

* Co hikes FY 2018 sales and adj. EPS forecast (Adds share movement, analyst comment, background, forecast details)

Celgene posts 9.5 percent rise in third-quarter profit

Oct 25 Celgene Corp on Thursday reported a 9.5 percent increase in third-quarter profit, led by higher sales of its flagship cancer drug, Revlimid, and strong demand for psoriasis treatment Otezla.

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Celgene profit tops expectations, will limit future price hikes

Celgene Corp on Thursday posted better-than-expected second quarter profit, powered by a 21 percent jump in sales of its blockbuster cancer drug Revlimid, and the U.S. biotech promised to limit future price increases on its medicines. The company joined several rivals in bowing to pressure from the administration of U.S. President Donald Trump to rein in rising costs of prescription drugs to U.S. patients.

UPDATE 2-Celgene profit tops expectations, will limit future price hikes

* Revlimid sales beat Wall Street estimates (Adds company, analyst comment, background, share movement)

Celgene quarterly profit drops 5 pct

July 26 U.S. drugmaker Celgene Corp reported a 5 percent drop in quarterly profit on Thursday, hurt by higher expenses.

BRIEF-Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival

* ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY

Select another date: